Microparticle technology refers to the creation and application of tiny particles with diameters ranging from a few nanometers to a few micrometers.

Cidara Therapeutics uses its Cloudbreak technology to develop novel drug-Fc conjugates. The company will showcase four posters at the AACR Annual Meeting.

4.1-4.7 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

Adcentrx Therapeutics will showcase early-stage findings of their Nectin-4 antibody-drug conjugate (ADC) initiative at the 2024 AACR Annual Convention.

AstraZeneca's Novel GR/β2AR Targeted Therapy for Asthma: Airsupra Approval and Its Implications for Treatment.

Carisma Therapeutics reported its Q4 financial results and year-end figures as of December 31, 2023, and provided a corporate update.

The FDA has cleared VOYDEYA™ for use alongside ravulizumab or eculizumab in managing extravascular hemolysis among adult patients with the uncommon disorder PNH.

Transdermal administration is a drug delivery method that involves the application of a medication on the skin to deliver therapeutic agents directly into the bloodstream.

Vertex Pharmaceuticals Incorporated revealed the progression of inaxaplin (VX-147) to the critical Phase 3 segment of the worldwide Phase 2/3 clinical study focusing on APOL1-related renal conditions.

TransCon PTH, developed by Ascendis Pharma, is an investigational prodrug of PTH hormone undergoing research and development.

Asha Therapeutics has revealed its selection of an innovative internal-binding compound, designated ASHA-624, intended as a treatment agent to alter the progression of Amyotrophic Lateral Sclerosis.

A drug interaction occurs when two or more drugs interact in the body, affecting the efficacy or safety of one or both medications.